Amgen's Cancer Drug Aces Trial

Here's some good news from Amgen. Their new cancer drug Lumakras achieved superior results to chemotherapy treatment Docetaxel, in a phase 3 study. In the study of 345 people, on average, patients taking Lumakras went 5.6 months without their cancer progressing versus 4.5 months for those taking Docetaxel.

25 percent of the patients on Lumakras lived for at least a year before their cancer got worse compared to 10 percent for the chemotherapy.

This is considered a very significant improvement, and the results in real-life will be even better, as people with early-onset cancers are treated with Lumakras immediately. This drug is already FDA approved (2021) and is used to treat adult patients with non-small lung cancer. Let's hope for the sake of cancer patients, and Amgen, that we continue to see such positive results. This one could be a real blockbuster.